Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Glenmark launches...

    Glenmark launches SGLT2 Inhibitor Remogliflozin under brand names Remo, Remozen

    Meghna A SinghaniaWritten by Meghna A Singhania Published On 2019-04-30T10:16:36+05:30  |  Updated On 16 Aug 2021 1:53 PM IST

    Glenmark will commercialize Remogliflozin in India under the brand names 'Remo' and 'Remozen'.


    Mumbai: In a major relief to diabetics, Glenmark Pharmaceuticals' has launched its novel, patent protected and globally-researched sodium glucose co-transporter -2 (SGLT2) inhibitor Remogliflozin etabonate (Remogliflozin) in India.


    Glenmark is the first company in the world to launch the novel SGLT2 inhibitor Remogliflozin and India is the first country to get access to this innovative drug. Glenmark will commercialize Remogliflozin in India under the brand names 'Remo' and 'Remozen'.


    A month ago, Medical Dialogues had reported that Mumbai-based Glenmark Pharmaceuticals Limited had sought approval from the IND Committee of the Central Drugs Standard Control Organisation (CDSCO) to manufacture and market Remogliflozin etabonate(RE) tablets of 100mg strength.


    Also Read: Diabetes Treatment: CDSCO expert panel marketing authorization Nod to Glenmark's SGLT2 Inhibitor Remogliflozin etabonate


    The genesis of Remogliflozin goes back to Japanese firm Kissei Pharmaceutical and later developed by GlaxoSmithKline (GSK) and BHV Pharma, an arm of US company, Avolynt. However, Glenmark secured certain rights to Remogliflozin via collaboration with BHV Pharma and carried out Phase-3 clinical trials on over 600 patients.


    The product is indicated for the treatment of Type 2 Diabetes Mellitus (T2DM) as monotherapy and in addition to the existing anti-diabetic therapies.


    Commenting on the launch, Sujesh Vasudevan, President, India Formulations, Middle East and Africa at Glenmark Pharmaceuticals said, "Globally, SGLT2 inhibitors are emerging as a preferred treatment for the management of type-2 diabetes and Glenmark is proud to introduce a novel molecule in this class, which is cutting-edge and researched extensively."


    "Diabetes is a key area of focus for Glenmark and with the launch of Remogliflozin, the company aims to improve access to SGLT2 inhibitors by providing an effective, high quality and world-class treatment option to patients in India, " he added.


    SGLT2 inhibitors are novel anti-diabetic drugs that help achieve glycemic control by acting on the SGLT2 receptors in the proximal tubule of the kidney, thereby preventing renal reabsorption of glucose and promoting excretion of glucose in the urine. SGLT2 drugs provide glycemic control, induce weight loss and reduce cardiovascular risks.


    The American Diabetes Association and the European Association for the Study of Diabetes have recommended the use of SGLT2 inhibitors as an alternative first-line treatment to Metformin or as an adjunctive treatment in the management of type-2 diabetes mellitus. SGLT2 inhibitors are particularly recommended for use in patients that have certain established cardiovascular diseases.


    India is estimated to have around 72 million adults living with diabetes, according to the International Diabetes Federation's Diabetes Atlas 2017.


    According to data from IQVIA, India's diabetes market is estimated at Rs. 11,413 crores (approx. USD 1630mn) as of MAT March 2019. The market size of SGLT2 inhibitors is estimated at Rs. 574 crores (approx. USD 82mn) as of MAT March 2019.


    As per a report in TOI, the drug is likely to be priced at 60 per cent lower than the price of the existing therapies. Remogliflozin will reportedly be priced at around Rs25 for daily therapy as against other drugs in the same class available in the range of Rs 55-60 per day, thereby disrupting the anti-diabetes market.

    blood sugarCDSCOCentral Drugs Standard Control OrganisationClinical Trialdiabetesdiabetes drugdiabetes manageentdrug safetyefficacyGlenmarkGlenmark PharmaceuticalsGlenmark REhealthhealth newsHealthcareIND Committeeinhibitormedicinespharma newspharma news indiaRERemoRemogliflozin etabonateRemozenSGLT2SGLT2 InhibitorSGLT2 inhibitorssugartype-2 diabetes
    Source : with inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Meghna A Singhania
    Meghna A Singhania

      Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok